Lenartova A, Randen U, Johannesen TB, et al. Richter syndrome
epidemiology in a large population based chronic lymphocytic leukemia cohort
from Norway. Cancer Epidemiol. 2019; 60: 128–133.
Rossi D, Spina V, Gaidano G. Biology and treatment of Richter
syndrome. Blood 2018; 131: 2761 LP – 2772.
Kanagal-Shamanna R, Jain P, Patel KP, et al. Targeted multigene deep
sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic
leukemia with disease progression and Richter transformation. Cancer 2019; 125:
Innocenti I, Rossi D, Trap? G, et al. Clinical, pathological, and
biological characterization of Richter syndrome developing after ibrutinib
treatment for relapsed chronic lymphocytic leukemia. Hematol Oncol. 2018; 36:
Guerrero-Hernandez M, Matas-Cespedes A, Serrat N, et al. Idelalisib
interferes with the crosstalk of follicular lymphoma and its immune
microenvironment and potentiates the activity of ABT-199. Blood. 2017; 130: 2813
LP – 2813.
Pham LV, Huang S, Zhang H, et al. Strategic therapeutic targeting to
overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res.
2018; 24: 3967 LP – 3980.